Lv1
10 积分 2023-10-03 加入
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
2天前
已完结
OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
2天前
已完结
Non-small-cell lung cancer
1个月前
已完结
Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs
3个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
4个月前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
5个月前
已完结
Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
5个月前
已完结
114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
5个月前
已完结
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment
5个月前
已完结
Is immune checkpoint inhibition part of standard therapy for stage III non‐small cell lung cancer?
5个月前
已完结
皖公网安备34019202002308
